Google Search

Search

Already a Member ?

Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Drug Intermediates, Speciality Chemicals, Raw Materials, Fine and Specialty Chemicals Intermediates, Pharmaceutical Bulk Drugs

Indian drugs and pharmaceutical industry has advanced perceptibly and is getting ready  for the new patent regime and  to withstand global competition, which is expected to be unleashed by new winds of liberalisation - a new era of liberalisation - much different from what was ushered in since the conclusion of the Uruguay Round and the establishment of the World Trade Organisation.

The industry has been expanding at annual rates ranging between 8 to 10% (against global growth rate of 6%).  According to a study  by McKinsey, Vision 2010, the domestic pharmaceutical industry could attain a size of  $25 billion (Rs 1200 billion) by 2010 by focusing on two areas: first, innovation-led research, development and new drug discoveries; and second, information technology-led remote sales and marketing.  The market for bulk drugs and formulations had increased from about Rs 103  billion in 1990-91 to an estimated Rs 435  billion at the end of 2003-04.  The prices of Indian essential drugs are among the lowest in the world. Apart from strides made by the industry in the last half-a-century, lower production cost due to reverse engineering and low R&D outlays has been a major factor in keeping the prices under check.

The global pharmaceutical industry is estimated at $ 300 billion, not all representing cross-border trade.  India's measly share of $ 1.5 billion in global trade represents an untapped potential. Under the regime of economic liberalisation underway since early 1990s, the drugs and pharmaceutical sector witnessed initiatives at fresh investment in the sector. Nearly 1735 investment proposals of the order of around Rs 166  billion were initiated. The foreign collaboration proposals approved numbered around 425 with a foreign direct investment  (FDI) component of over Rs 25 billion. The pharmaceuticals have figured high on the export front. In 2001-02,  the sector was  estimated to have registered a growth of 17.6% at around Rs 20.3 billion.

In the wake of economic liberalisation, many a  overseas players  returned or contemplated returning to India. These include Ivox Corp (USA),  Taro Pharmaceuticals (Israel) and Merck (USA). These are out either to set shop or looking for acquisitions in India. Hexal AG of Germany has established a liaison office in India. MILLIONCs like Rocha, Bayer, Aventis and Chiron are making India a regional hub for bulk drugs. 

The Export Import Bank of India (Exim Bank) had  doubled its corpus for the pharmaceutical industry to Rs 2 billion as a result of increased activity in the industry, especially in the external sector. The fund is used for the development and commercialisation of the new products and applications, significant improvement in the existing design of  products, setting up and expansion of pilot plants, research studies for obtaining regulatory approvals, cost of filing and managing international patent and R&D Centres.

It needs, however, to be recognised that the presence  of small scale manufacturers has resulted, on the one hand,  in a highly fragmented industry, and on the other, it has made it possible to supply a near 100,000 drugs including vitamins, antibiotics, antibacterials, cardio-vascular and other essential drugs. These account for nearly 37% of the market.  While each of about 80% of the manufacturers has annual sales below a billion rupees, top ten companies are known to control over 30% of the market. At present there are more than 20,000 players in the country.

The major players are: Alembic Chem, Aurobindo Pharma, Cipla, Dr. Reddy's, FDC, IPCA Labs, Jagsonpal Pharma, J.B. Chemicals, Kopran, Lupin Labs, Lyka Labs, Morepan Labs, Nicholas Piramal, Ranbaxy Labs, Sun Pharma, Themis Medicare, GlaxoSmithkline, Astrazeneca, Aventis, E-Merck, Torrent Pharma, TTK Healthcare, Unichem Labs,  Wockhardt  and  Zandu Pharma.  Until recently, only a few of the Indian companies had gone into any serious R&D activity. Much of the effort was directed to affordable analogue research. The R&D level in the country is low with even well-placed pharma companies spending less than 2% of turnover on R&D. MILLIONCs are known to contribute as much as 10% or more of their turnover to R&D.  While India is very strong in process chemistry, biology and applied bio-chemistry, initiatives at all levels - government, academia, private sector - involving heavy financial outlays, are called for.

Ayurveda continues to remain a preferred system of medicine for a vast segment of population in the country. The country has over 400,000 registered practitioners of the Indian system of medicine. Around 170 institutes properly affiliated to various universities impart under- or post-graduate courses each year. These institutes churn out some 5,500 fresh practitioners. The practitioners are supported by 12,000 dispensaries and 2,100 beds available for ayurveda treatment countrywide. The emerging biotechnology sector has already taken by storm and is offering sops to states to make these as the thriving ground for the highly potential segment in medicare.

How to Prepare Project Report on Pharmaceutical Processing Industry?

Drug manufacturing companies work under strict laws and regulations. Their processes need to comply with relevant drugs act in their respective countries.

Therefore, if you are planning to invest in pharmaceutical processing, a good project report will be necessary. Besides the prominent aspects of a project report, you should pay close attention to the following issues in a pharmaceutical processing report.

1. Marketing

This industry is very competitive. I need not stress the value of detailed market analysis. You need to understand the status of market competition and the demand for pharmaceutical products. A proper market analysis will additionally help you prepare an excellent pharmaceutical business plan. Given your market analysis report, you will develop a marketing plan.

2. Government approval

In almost all countries, there are laws and regulations for the manufacture, distribution, and administration of drugs. Consider giving a status report on these requirements when making the final project status report.

3. Manufacturing Process

It would help if you had a picture of the process you will employ in making your drugs. Outline the quality checks and balances in the process. State the required pharmaceutical intermediates and their corresponding active pharmaceutical ingredients.

4. Machines and Equipment

You need to identify the equipment you will need, such as homogenizers, spectrophotometer, tabulating machines, etc. to ensure the machines meet quality specifications. You may also need to put down a plan to train workers on their operations.

How Does the Drug Manufacturing Process Work?

If you are an aspiring drug manufacturer, you should know how the bulk drug manufacturing process works. This is a complicated process and requires professional skills in molecular biology, medical microbiology, and pharmacy.

The process involves four steps, namely:

  • Milling
  • Granulation
  • Coating
  • Tabulation

Milling is important because it makes the drug powder uniform. It ensures uniform distribution of the active pharmaceutical ingredients. Additionally, milling makes it easier to formulate the drug into a syrup or emulsion.

After milling, you can use wet or dry granulation to form granules. You then coat them and compress the drugs using a tabulating machine. Alternatively, you can fill the granules into capsules.

For any chemical industry business ideas, prioritize the security of your staff. Ensure workers have sufficient PPEs. Have plans to protect them from chemical poisoning. Install eyewashes and emergency showers in both production units and laboratories.

Pre-Feasibility Report on Bulk Drug Manufacturing Process

Before you set up a feasibility report or start making a business plan, you first need to do a pre-feasibility study. It is the conclusions of this study that will make you decide whether to proceed to the project feasibility report or not.

Implementing a pharmacy business plan is an expensive affair. Please do not put any investment into a business plan of this magnitude without looking at its feasibility study report.

Considering the variety of pharmaceutical products, a feasibility plan will help you decide on the most relevant product for your target market. The results of pre-feasibility and feasibility studies will inform your marketing strategy plan. At the pre-feasibility stage, you get to review the technical skills required for the bulk drug manufacturing process. You also assess the knowledge level and determine whether you have the knowledge and skills.

Lastly, this report looks at the financial demands of a chemical project report on bulk drug processing. From here, you will decide on the feasibility of the project.

How to Grow Pharmaceutical Intermediates Market?

The pharmaceutical industry relies on pharmaceutical intermediates. We use these chemicals to produce active pharmaceutical ingredients (API). 

To grow the pharmaceutical intermediates market, therefore, we should focus on the drug manufacturing industry. Here are some tips on how we can grow this industry.

1. Investment in Research and Development

We should encourage governments and established drug manufacturers to invest in research and development of new medicines. New drug development will increase the need for pharmaceutical intermediates. Consequently, this will cause the growth of the industry.

2. Boost Generic Drug Manufacturing

Feasibility study reports for project ideas in pharmaceuticals show a growing demand for generics. This demand is particularly high in developing countries. More investment in generic drugs will result in increased demand for pharmaceutical intermediates.

3. Collaborations

It is quite expensive to run a pharmaceutical intermediate processing company. If you look at a project summary example for the local industry and you will notice the huge investment. One way of cushioning the industry is to encourage collaborations, mergers, and acquisitions. Working together gives small-scale companies a competitive advantage. It lowers their operation costs and improves revenue.

How to Set Up a Chemical Industry Business Plan?

Writing a chemical industry business plan begins with a pre-feasibility study. Here, you look at the various business ideas in chemical manufacturing. You then evaluate each of these ideas based on:

1. Skills and Knowledge

If you are interested in the chemical manufacturing industry, I assume that you have some skills or knowledge in this sector. If so, look at the skills required for each idea you have. Which of these ideas marches your skills and knowledge?

2. Financial Resources

Different chemical processes have different cost implications. Try to review each idea against the expected financial input. You can examine some business plan examples on the internet to get a hint on required inputs. Once you have a convincing pre-feasibility report, you can proceed to make a feasibility report meaning the idea is profitable and viable.

The next step in setting up a chemical industry business plan is to prepare a small business marketing plan. The results of your feasibility report will help do this.

Chemical manufacturing is not only expensive, but it is also strictly regulated by law. It would be best if you had an innovative marketing strategy to break even. It would be best if you did an accurate market analysis.

A project report on the pharmaceutical industry helps you assess the dynamics of the industry. You will want to know who the major chemical manufacturers are. You will also assess the availability of raw materials and machinery for your pharmaceutical industry.

In your project report, you will also address the technical aspects of the pharmaceutical manufacturing process. You need to draw a flow diagram for the process. Lastly, sit down and draw a business plan for your chemical industry business. You will need the information from all the above processes. Additionally, a business plan will consider the financial implications of your pharmaceutical industry project report.


We can provide you detailed project reports on the following topics. Please select the projects of your interests.

Each detailed project reports cover all the aspects of business, from analysing the market, confirming availability of various necessities such as plant & machinery, raw materials to forecasting the financial requirements. The scope of the report includes assessing market potential, negotiating with collaborators, investment decision making, corporate diversification planning etc. in a very planned manner by formulating detailed manufacturing techniques and forecasting financial aspects by estimating the cost of raw material, formulating the cash flow statement, projecting the balance sheet etc.

We also offer self-contained Pre-Investment and Pre-Feasibility Studies, Market Surveys and Studies, Preparation of Techno-Economic Feasibility Reports, Identification and Selection of Plant and Machinery, Manufacturing Process and or Equipment required, General Guidance, Technical and Commercial Counseling for setting up new industrial projects on the following topics.

Many of the engineers, project consultant & industrial consultancy firms in India and worldwide use our project reports as one of the input in doing their analysis.

We can modify the project capacity and project cost as per your requirement.
We can also prepare project report on any subject as per your requirement.

Page 21 of 21 | Total 203 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 21   »

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Select all | Clear all Sort by

Manufacturing of I.V. Fluids (BFS Technology).

Production of I.V. Fluids (BFS Technology). Profitable Business of Intravenous Solutions, Intravenous Fluids. Intravenous fluids are fluids that are supposed to be administered to a patient intravenously, directly through the circulatory system. These fluids should be sterile to protect patients from injury, and there are variety of various varieties out there to be used. Intravenous fluids also can be used as a route of medication administration. If a doctor wants to deliver a small quantity of medication over an extended period of your time, it will be dissolved {in adoring in an exceedingly in a very} bag of intravenous fluids and set on an infusion pump that delivers the medicated fluid directly into the blood. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Advantages of BFS Technology: ? Blow-fill-seal technology enables the manufacture of preservative-free single-unit doses. PreservatI.V.es are recognized as potentially harmful to the sensitive mucosae of the eyes, nose, and lungs, so this is an enormous benefit to sensitive patients. ? Another advantage of unit-doses is that they ensure that the patient takes the correct amount of product, especially when dealing with highly potent compounds, i.e. those therapeutically active at a low concentration. ? Sterile unit-doses are portable and easy to use individually, excellent properties for today’s active lifestyles. Blow-fill-seal (BFS) single doses are an ideal solution for use in ophthalmology, respiratory diseases, rhinology, and antisepsis and wound care. ? Blow-fill-seal technology reduces personnel intervention making it a more robust method for the aseptic preparation of sterile pharmaceuticals. BFS is used for the filling of vials for parenteral preparations and infusions, eye drops, and inhalation products. Generally the plastic containers are made up of polyethylene and polypropylene. Polypropylene is more commonly used to form containers which are further sterilized by autoclaving as polypropylene has greater thermo stability. ? Blow Fill and Seal technology is mainly used for pharmaceutical solutions. The examples of pharmaceutical solutions that can be packaged are injectable solutions, antibiotics, ophthalmological drops, suspensions, infusion solutions, solutions for dialysis, solutions for irrigation and solutions for hemofiltration. ? The basic concept of BFS is that a container is formed, filled, and sealed in a continuous process without human intervention, in a sterile enclosed area inside a machine. Thus this technology can be used to aseptically manufacture sterile pharmaceutical liquid dosage forms. Features: 1. 100% film utilization: No waste edge between bags, reducing both material and energy consumption. 2. Special I.V. bag design: each bag saves 10mm film than others. 3. Reliable heating and welding system: Leakage rate less than 0.03%. 4. Quick changeover: 0.5-1 hour to switch from one size to another. 5. Stable transmission system: only needs 1 control system, 1 HMI and 1 operator. 6. Safe filling nozzle: No solution overflows, no particles generation. 7. Auto faulty rejection system detected by the machine. 8. Production line length is reduced by 1/3, both workshop and air conditioning and cleaning area are reduced by 1/3, greatly reducing the initial investment and future running cost. 9. Simple structure, more stable and reliable performance. Related Videos: - https://bit.ly/2UI2SEL Uses and Applications ? There are four main ranges of application of highly specialized intravenous infusion solutions: ? Treatment of discarded water and electrolyte metabolism, especially in severe cases. ? Therapy of acid base in balances. ? The volume substitution and volume replacement in surgery of accident victim suffering blood loss. ? Paratral nutrition for severally ill and post-operative patients. ? Aqueous isotonic injection (5%) of dextrose is given as intravenous injections to increase the column of circulating blood in the shocks and hemorrhages and to counteract dehydration. When it is desired to replace excessive salt loss also glucose is injected along with sodium chloride. ? Dextrose solution is used during postoperative period when sodium extraction is reduced. ? Dextrose solution with concentration of 10-15% is used as diuretic for increase in urine flow. ? Dextrose solutions of 5% normal saline are used for restoring fluid volume in circulation of an emergency as in accidents with hemorrhage. ? Saline solution is used when large amount of sodium has been lost by vomiting or by gastric or intestinal duodenal aspiration or through an alimentary fistula. ? Dextrose monohydrate is used as supplement to cow's milk in part of feeding. ? Hypertonic dextrose solution (25-50%) is in medical treatment partly because they are believed to strengthen heart muscles. Hypertonic solutions are used in intravenous injection to relieve intractable pressure in-patient with hydrocephalus and meningitis. Market Outlook Technologies utilized in the production of IV fluids are Blow-Fill-Seal (BFS) Technology and type fill seal (FFS) technology. BFS and FFS are a variety of advanced aseptic manufacturing technique, in which the container is created (in case of BFS and in FFS pouch is formed), filled, and sealed in one continuous, automated system. A primary advantage of those technologies is to reduce human intervention, which is able to reduce the risk of microorganism contamination and foreign particulates. Thus, these technologies are wont to aseptically manufacture sterile pharmaceutical liquid. Related Videos: - Production of I.V. Fluids (Saline and Dextrose) IV Fluids (FFS) Technology I.V. (Intravenous Liquids) Fluids Manufacturing Unit. The primary costumers for these manufacturing units are Hospitals, Clinics, Dialysis centers, Home care settings. The global Intravenous Fluid market size was valued at US$ 8,372.0 million in 2019 and is expected to witness a CAGR of 6.1% over the forecast period (2019 – 2027). The emergence of the IV Fluid market is attributed to the fast-growing geriatric population and the presence of malnutrition in the elderly and pediatric population. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Increasing launches and regulatory approvals for Intravenous Fluid injection is expected to drive the growth of the global Intravenous fluid market. Launches of new Intravenous fluid injections for the treatment of various diseases such as dehydration, gastrointestinal diseases are expected to drive the Intravenous fluid market growth Demand & Market Growth Rates of I.V. Fluid Sets in India: Past and Future Year Bottles in Million 2015-16 2885 2016-17 3210 2017-18 3570 2018-19 3945 2019-20 4375 2024-25 7200 COST ESTIMATION Six Cavity 500 ml Bottles : 39,600 Bottles per Day Eight Cavity 500 ml Bottles : 30,800 Bottles per Day Cost of Machinery : Rs. 46,50,0000 Key Players:- ? Abaris Healthcare Pvt. Ltd. ? Ahlcon Parenterals (India) Ltd. ? Axa Parenterals Ltd. ? Infutec Healthcare Ltd. ? Kokad Pharmaceutical Laboratories Ltd. ? Parenteral Surgicals Ltd. ? Pharmazell (India) Pvt. Ltd. Tags:- #IVFluids #IntravenousFluids #Fluid #ivbottles #Intravenous #IVtherapy #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #pharmaceutical #pharma #pharmaceuticalbusiness #Pharmacy #PharmaceuticalReport #pharmaceuticalprojects
Plant capacity: 70,400 Bottles per DayPlant & machinery: 465 Lakhs
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Active Pharma Ingredients (API) Amoxicillin Trihydrate, Azithromycin & Paracetamol

Active pharmaceutical ingredients are the active substances that are used in the manufacture of a drug and have a pharmacological effect. They provide health benefits and play a vital role in disease diagnosis, prevention, and treatment. Active pharmaceutical ingredients may be synthesized either chemically or through biotechnological methods. Azithromycin is used to treat certain bacterial infections, such as bronchitis; pneumonia; sexually transmitted diseases (STD); and infections of the ears, lungs, sinuses, skin, throat, and reproductive organs. Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. India is the seventh largest country in the world and has the second highest population. It has a parliamentary democratic form of government and has abundant natural resources and sufficient oil reserves. Huge investment promises from different countries predict a bright future for India. It has a well-developed administration and an independent judicial system with an ever-growing consumer base. It has a huge pool of hard-working skilled workers in all fields. The government has set up tax and non-tax incentives to establish new industrial entities in specific sectors, which include energy, ports, highways, electronics, and software. The Make in India initiative was launched by the government in 2014 and received an excellent response from the developed nations. The government has also created special areas dedicated to export, called export-processing zones (EPZs) or special economic zones (SEZs), to encourage foreign investment. The global active pharmaceutical ingredient market size is expected to reach a value of USD 286.6 billion by 2027, registering a CAGR of 6.7% over the forecast period. Factors, such as increasing preference for outsourcing APIs and growing prevalence of various target diseases such as cancer and Cardiovascular Diseases (CVDs) are expected to drive the market growth. Patent expirations of blockbuster drugs give rise to generic versions of these molecules, wherein the manufacturers bear the cost. After a patent expires, R&D investments done by the company are no longer beneficial for the company. API production requires a huge capital amount as the process needs extremely systematic protocols. Thus, pharmaceutical companies benefit from outsourcing API production, as it eliminates the need for labor force and installing expensive manufacturing units. Strategic outsourcing allows companies to focus on their core competencies, ultimately resulting in increased productivity. These factors are also projected to drive the active pharmaceutical ingredient market growth. The growth of active pharmaceutical ingredients market is marked by the huge demand for drugs like analgesics, anti-infectives and diabetes, and pain management drugs. But with the rising trend of increasing research and development (R&D) activities, the demand is experiencing a shift towards the advancement of complex APIs that find use in novel formulations, thereby targeting niche therapeutic areas. This facilitates the development of new technologies and ensures a high quality product. Among the problems for pharmaceutical supply chains during this pandemic are the restrictions and impact of COVID-19 on two of the largest global producers of active pharmaceutical ingredients (APIs) and generics: China and India. APIs is a crucial part of the pharma industry’s strategic plan to combat the COVID-19 pandemic. The majority of APIs for generic drug manufacturing across the globe are sourced from India, which also supplies approximately 30 percent of the generic APIs used in the US. However, Indian manufacturers rely heavily on APIs from China for the production of their medicine formulations, procuring around 70 percent from China, the top global producer and exporter of APIs by volume. Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Few Indian major players are as under Alpha Remedies Ltd Ankur Drugs & Pharma Ltd. Cian Healthcare Ltd Farmson Pharmaceutical Gujarat Pvt. Ltd. Glaxosmithkline Pharmaceuticals Ltd. Pan Drugs Ltd Piramal Enterprises Ltd.
Plant capacity: Paracetamol : 1,000.0 Kgs / day Azithromycin : 500.0 Kgs / day Amoxicillin Trihydrate: 500.0 Kgs dayPlant & machinery: 175 lakhs
Working capital: -T.C.I: Cost of Project : Rs 1322 lakhs
Return: 29.00%Break even: 47.00%
Add to Inquiry Add to Inquiry Basket

Manufacturing of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol).

Production of Active Pharma Ingredients (API) (Amoxicillin Trihydrate, Azithromycin & Paracetamol). Investment Opportunities in Pharmaceutical Industry. An active ingredient (AI) is that the ingredient in an exceedingly pharmaceutical drug that's biologically active. The similar terms active pharmaceutical ingredient (API) and bulk active i.e. bulk medicine are utilized in medicine, and therefore the term active substance could also be used for natural products. Thus, depending on the drug’s administered dosage, the reactions and results differ. Certain drugs are comprised of more than one kind of API. Amoxicillin is an antibiotic used to treat variety of bacterial infections. These include middle ear infection, strep throat, pneumonia, skin infections, and tract infections among others. It’s taken orally, or less usually by injection. Active Pharmaceutical Ingredient (API), is that the term used to check with the biologically active component of a drug product (e.g. tablet, capsule). Drug products are typically composed of many elements. The aforementioned API is that the primary ingredient. Alternative ingredients are commonly known as "excipients" and these substances are always required to be biologically safe, often making up a variable fraction of the drug product. The procedure for optimizing and compositing this mixture of components utilized in the drug is known as "formulation." Paracetamol is a commonly used medicine that can help treat pain and reduce a high temperature (fever). It is often recommended as one of the first treatments for pain, as it's safe for most people to take and side effects are rare. Azithromycin is an antibiotic used for the treatment of variety of bacterial infections. This includes middle ear infections, strep throat, pneumonia, traveler's diarrhea, and bound alternative intestinal infections it also can be used for variety of sexually transmitted infections, as well as chlamydia and gonorrhea infections. At the side of alternative medications, it's going to even be used for malaria. It may be taken by mouth or intravenously with doses once per day. It is on the world Health Organization's List of Essential Medicines, the safest and most effective medicines required in a very health system. It’s one in all the most usually prescribed antibiotics in children. Trim ox is on the market as a generic medication. Related Books: - Pharmaceutical, Drugs, Proteins Technology Handbooks Azithromycin alone and in combination with different medications is currently being studied for the treatment of coronavirus wellness 2019 (COVID-19). Currently, azithromycin has been used with hydroxychloroquine to treat certain patients with COVID-19. However, there are mixed reports of effectiveness once azithromycin was used at the side of alternative medications to treat other viral respiratory infections. Azithromycin also has been used to treat bacterial infections in hospitalized patients with COVID-19. A lot of information is required before any conclusions may be made regarding the possible advantages and risks of using azithromycin either alone or together with hydroxychloroquine in patients with COVID-19. Amoxicillin Trihydrate may be a hydrate that's the Trihydrate type of amoxicillin; a semisynthetic antibiotic, used either alone or together with potassium clavulanate (under the name Augmentin) for treatment of a variety of bacterial infections. It’s a role as an antibacterial drug and an antimicrobial agent. It contains an amoxicillin. Manufacturing Process The manufacturing process of Paracetamol is summarized in the following steps: -charge acetic acid to the reactor. -add p-nitro phenol as a starting material and iron powder as catalyst. -Heat to temp 80-90 ºC. -The reaction is exothermic and temp will rise to 130 ºC. -After slight cooling -Reflux the reaction at 118ºC for 3-4 hours. -Cool to 60 ºC. -Add methanol to the reaction. -Reflux for 1 hour. -distill the methanol and recycle. -Add water to the obtained cake. -And make a solution -Add activated carbon. -Filter -Dry the cake. -Pulverize the dry cake to get the Paracetamol fine powder. Applications:- Communicable Diseases Oncology Diabetes Cardiovascular Diseases Pain Management Respiratory Diseases Other Therapeutic Applications Role of Government towards API The coronavirus outbreak disrupting supply of active pharmaceutical ingredients (APIs) and medical devices from China to India, the government has come out with four schemes worth Rs 13,760 crore to encourage manufacturing of bulk drugs and medical devices in the country and their exports. On March 21, the Union Cabinet under the chairmanship of Prime Minister Narendra Modi had approved an expenditure of Rs. 9,940 crore and Rs. 3,820 crore for APIs and medical devices, respectively. The Cabinet also approved a scheme on promotion of bulk drug parks for financing common infrastructure facilities in three bulk drug parks with financial implication of Rs. 3,000 crore for next five years. The government will give grants-in-aid to states with a maximum limit of Rs. 1,000 crore per bulk Drug Park. Parks will have common facilities such as solvent recovery plant, distillation plant, power and steam units, common effluent treatment plant etc. The government further approved production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical KSMs/drug intermediates and APIs in the country with financial implications of Rs. 6,940 crore for next eight years. Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. Rate of incentive will be 20 per cent (of incremental sales value) for fermentation based bulk drugs and 10 per cent for chemical synthesis based bulk drugs. The PLI scheme will lead to expected incremental sales of Rs. 46,400 crore and significant additional employment generation over eight years. The drug industry has welcomed the incentives offered by the government to promote API units in India. Besides APIs, the Cabinet also approved the scheme for promotion of medical device parks in the country in partnership with the states. A maximum grant-in-aid of Rs. 100 crore per park will be provided to the states. It will have financial implications of Rs. 400 crore. The PLI scheme for promoting domestic manufacturing of medical devices will have financial implications of Rs. 3,420 crore for next five years. Medical device is a growing sector and its potential for growth is the highest among all sectors in the healthcare market. It is valued at Rs. 50,026 crore for 2018-19 and is expected to reach to Rs. 86,840 crore by 2021-22. India depends on imports up to an extent of 85 per cent of total domestic demand of medical devices. Union Cabinet scheme on Promotion of Bulk Drug Parks • The scheme on Promotion of Bulk Drug Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years. • Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/Drug Intermediates and APIs in the country with financial implications of Rs6,940 crore for next eight years. Details: Promotion of Bulk Drug Parks • Decision is to develop 3 mega Bulk Drug parks in India in partnership with States. • Government of India will give Grants-in-Aid to States with a maximum limit of Rs. 1000 Crore per Bulk Drug Park. • Parks will have common facilities such as solvent recovery plant, distillation plant, power & steam units, common effluent treatment plant etc. • A sum of Rs. 3,000 crore has been approved for this scheme for next 5 years. Production Linked Incentive Scheme • Financial incentive will be given to eligible manufacturers of identified 53 critical bulk drugs on their incremental sales over the base year (2019-20) for a period of 6 years. • Out of 53 identified bulk drugs, 26 are fermentation based bulk drugs and 27 are chemical synthesis based bulk drugs. • Rate of incentive will be 20 % (of incremental sales value) for fermentation based bulk drugs and 10% for chemical synthesis based bulk drugs. • A sum of Rs. 6,940 crore has been approved for next 8 years. Market Outlook Active Pharmaceutical Ingredient Market is valued at USD 172.69 Billion in 2018 and expected to reach USD 263.80 Billion by 2025 with the CAGR of 6.24% over the forecast period. The increasing incidence of chronic diseases, growing importance of generics, and the increasing uptake of biopharmaceuticals are some of the major factors driving the growth of the global APIs market. On the other hand, the unfavorable drug price control policies across various countries and the increasing penetration of counterfeit drugs are expected to restrain the growth of this market in the coming years. Related Projects: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates Drugs and over-the-counter (OTC) drugs. In 2019, the prescribed drugs segment is expected to account for the most important share of the APIs market. The demand for drugs falling under this class has increased significantly in recent years because of the rising prevalence of target diseases. Additionally, the most important share of the prescription drugs segment also can be attributed to the increased focus of innovator corporations on the development of specialty drugs and affordability of health care. The implementation of significant federal reforms to improve the affordability of healthcare, especially in the, us has expanded the consumption of each traditional and specialty medicine. Also, inflation has played a key role in enhancing revenue from the sales of prescription drugs, significantly specialty drugs. All these factors are collectively responsible for the large share of this phase. Based on the kind of drug, the APIs market can be classified into two segments prescribed. Manufacturer Insights On the basis of type of manufacturer, the API market has been segmented into merchant and captive APIs. Captive API command the most important share in 2019 because of simple availability of raw materials and intensive capitalization of major key players for the development of high-end manufacturing facilities. API is calculable to be the fastest-growing segment over the forecast period. The segment growth is driven by factors similar to high cost of in-house manufacturing of those molecules and rising demand for biopharmaceuticals. Related Videos: - Pharmaceutical, Drugs, Fine Chemicals, Bulk Drug Intermediates, Pharmaceutical Drugs, Pharma Drug Ingredients Intermediates, Pharmaceutical Bulk Drugs Active Pharmaceutical Ingredient (APIs) are portions of any drugs that are biologically active in nature. The APIs have significant use in the manufacturing of effective and safe medicines. Depending on the drug’s administered dosage, the reactions and results take issue according to the requirement and use for specific treatment of diseases. Sure medicine are contained of over one kind of API. medicine are chosen primarily for his or her active ingredients to treat variety of chronic and infectious diseases similar to diabetes, cancer, arthritis, bone & joint infections, pneumonia, otitis, streptococcal pharyngitis, cellulites, and tract infections. However, the standard will vary widely from one whole to a different. Medicine are chosen primarily from active ingredients within the liquid or solid form like tablet or alternative throughout. Global Active Pharmaceutical Ingredient Market Dynamics The key issue for growth of worldwide Active Pharmaceutical Ingredient market is that the rise of demand for the new drug discovery for treatment of various chronic and infectious diseases like HIV, cancer, arthritis, bone & joint infections, hepatitis-B, Aids etc. across the world. According to WHO in 2018, the worldwide cancer burden has up to 18.1 million new cases as well as 9.6 million deaths across the world. Because of such rise within the cases of cancer, the new drugs discovery using the Active Pharmaceutical Ingredient has become essential. Recently in line with the American Chemical Society in 2019, there has been 48 new drugs has been approved by the fad U.S. out of that 11 for new cancer treatments with the innovative molecular pharmaceutical ingredients. However, the Active Pharmaceutical Ingredient market is hampered by would like for prime investment with huge capital demand for research and developments. Moreover rising health cautiousness among the people with technological advancement immense investment for launching of recent drugs and biological products, acquisitions, collaborations, and regional growth can provide huge opportunity for Active Pharmaceutical Ingredient market. For instance in 2019, Raquel has been acquired by Merck & Co. for roughly around USD 2.7 billion in cash, for making cancer drug using Active Pharmaceutical Ingredient with the most recent small-molecule-focused. Expansion of Manufacturing Facilities Creating Lucrative Opportunities for Market Growth Majority of specialty API companies are increasing their manufacturing facilities for specialty active pharmaceutical ingredients (API) to take care of or gain market share. Substantial investments within the growth of approved specialty active pharmaceutical ingredients (API) is one in all the most important factors among key players in the specialty active pharmaceutical ingredients (API) market. For instance, in early 2020, Wuxi STA opened oligonucleotide API manufacturing facility in Changzhou, China to cope up with the increasing demand. In 2018, Cordon Pharma expanded operations with new commercial oligonucleotide active pharmaceutical ingredients (API) manufacturing capabilities at its FDA inspected Colorado facility. The emergence of COVID-19 has brought the world to a standstill. We perceive that this health crisis has brought an unprecedented impact on businesses across industries. However, this too shall pass. Rising support from governments and several companies will help within the fight against this highly contagious disease. There are some industries that are struggling and some are thriving. Overall, almost each sector is anticipated to be impacted by the pandemic. Focus on healthcare to drive the active pharmaceutical ingredients market The spending on healthcare has grown at a rapid pace in recent years and it increased at a CAGR of 6.92% between the years 2003 and 2013. The healthcare spending growth was significantly higher than the population growth rate that grew at a CAGR of 1.22% for the same period. The per capita healthcare spending rose from just under US$ 600 in 2003 to above US$ 1000 in 2013, at an average CAGR of 5.62%. The focus on healthcare spending was observed to be a global phenomenon and this directly benefited the active pharmaceutical ingredients market. Related Videos: - Active Pharma Ingredients (API) - Global Market Estimated to Reach US$ 21.9 billion by 2023 Investment Opportunities in API Bulk Drugs & Intermediates Manufacturing Unit Production of Paracetamol (Acetaminophen), bulk pharmaceutical active ingredient Investment Opportunities in APIs KSMs Drug Intermediates Bulk Drug Industries Manufacturing Business Ideas in Pharmaceutical Industry Key Players Pfizer, Inc. (US), Novartis AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (US), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (US), GlaxoSmithKline plc (UK), Merck & Co., Inc. (US), AbbVie Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), and AstraZeneca plc (UK). Sun Pharmaceutical Industries Ltd. Tags:- #Activepharmaingredients #pharmaingredients #IndianPharma #medicineingredients #paracetamolingredients #amoxicillinTrihydrate #Azithromycin #COVID19 #Paracetamol #coronavirus #CoronavirusBusiness #COVID2019 #CaronaBUSINESS #lockdownbusiness #businessinlockdown #coronavirusbusiness #Entrepreneurs #covid19business #DetailedProjectReport #businessconsultant #BusinessPlan #feasibilityReport #NPCS #industrialproject #entrepreneurindia #startupbusiness #startupbusinessideas #businessestostart #startupideas #startupbusinesswithnomoney #businessstartupindia #API
Plant capacity: -Plant & machinery: -
Working capital: -T.C.I: -
Return: 1.00%Break even: N/A
Add to Inquiry Add to Inquiry Basket

Information
  • One Lac / Lakh / Lakhs is equivalent to one hundred thousand (100,000)
  • One Crore is equivalent to ten million (10,000,000)
  • T.C.I is Total Capital Investment
  • We can modify the project capacity and project cost as per your requirement.
  • We can also prepare project report on any subject as per your requirement.
  • Caution: The project's cost, capacity and return are subject to change without any notice. Future projects may have different values of project cost, capacity or return.

Add multiple items to inquiry
Select the items and then press Add to inquiry button

Page 21 of 21 | Total 203 projects in this category
« Previous   Page 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 .... 20 21   »

About NIIR PROJECT CONSULTANCY SERVICES

Hide »

NIIR PROJECT CONSULTANCY SERVICES (NPCS) is a reliable name in the industrial world for offering integrated technical consultancy services. NPCS is manned by engineers, planners, specialists, financial experts, economic analysts and design specialists with extensive experience in the related industries.

Our various services are: Detailed Project Report, Business Plan for Manufacturing Plant, Start-up Ideas, Business Ideas for Entrepreneurs, Start up Business Opportunities, entrepreneurship projects, Successful Business Plan, Industry Trends, Market Research, Manufacturing Process, Machinery, Raw Materials, project report, Cost and Revenue, Pre-feasibility study for Profitable Manufacturing Business, Project Identification, Project Feasibility and Market Study, Identification of Profitable Industrial Project Opportunities, Business Opportunities, Investment Opportunities for Most Profitable Business in India, Manufacturing Business Ideas, Preparation of Project Profile, Pre-Investment and Pre-Feasibility Study, Market Research Study, Preparation of Techno-Economic Feasibility Report, Identification and Selection of Plant, Process, Equipment, General Guidance, Startup Help, Technical and Commercial Counseling for setting up new industrial project and Most Profitable Small Scale Business.

NPCS also publishes varies process technology, technical, reference, self employment and startup books, directory, business and industry database, bankable detailed project report, market research report on various industries, small scale industry and profit making business. Besides being used by manufacturers, industrialists and entrepreneurs, our publications are also used by professionals including project engineers, information services bureau, consultants and project consultancy firms as one of the input in their research.

^ Top